No-Test Medication Abortion: A Systematic Review

Marit Pearlman Shapiro, D. Dethier, M. Kahili-Heede, B. Kaneshiro
{"title":"No-Test Medication Abortion: A Systematic Review","authors":"Marit Pearlman Shapiro, D. Dethier, M. Kahili-Heede, B. Kaneshiro","doi":"10.1097/01.ogx.0000923080.61269.5e","DOIUrl":null,"url":null,"abstract":"The use of medication abortion has increased significantly in the past several years, in part due to the increased adoption of telemedicine during the COVID-19 pandemic. Several leading organizations have established recommendations for the practice of providing a medication abortion without a prior pelvic examination or ultrasonogram (no-test medication abortion). Evidence demonstrates that gestational age can be accurately measured with patient screening questions and the risk of ectopic pregnancy among women seeking medication abortion is very low. Given this paradigm shift in abortion access, increasing numbers of health care professionals worldwide have adopted these practices and published their results. This systematic review aimed to summarize the efficacy and safety outcomes of medication abortion performed without prior pelvic examination or ultrasound. Ongoing and published clinical trials were identified, and randomized control trials and comparative cohort trials discussing the provision of no-test medication abortion were eligible. The primary study outcome was successful medication abortion, defined as complete abortion without the need for surgical management. Failure was thus defined as the need for surgical intervention to complete the abortion. Medication regimens, efficacy rates, complication rates, and adverse events were ed from eligible studies. A total of 21 studies were included in this review, including cases performed in over 24 countries. Ultimately, 15 studies were sufficiently homogenous in terms of design and comparator to create aggregate data with summary statistics for the primary outcome. The overall efficacy rate of no-test medication abortion was found to be 96.4% (95% confidence interval [CI], 96.096.7) in the 10,693 patients included in this review. Among pregnancies at less than 70 days' gestation (n = 8166), the efficacy rate was 95.2% (95% CI, 94.795.7). The rate of surgical intervention was 4.4% (95% CI, 4.04.9), and at less than 70 days' gestation was 3.8% (95% CI, 3.34.3). The ectopic pregnancy rate was 0.06% (95% CI, 0.020.15), blood transfusion rate ranged from 0% to 0.7%, and there were no deaths reported. The results of this systematic review encompassing data on 10,693 patients showed demonstrate that no-test medication abortion is likely effective and safe. The rates of surgical evacuation and complication were comparable with the rate among those undergoing medication abortion with pretreatment ultrasound, and significantly lower than the rates seen with unsafe methods of abortion.","PeriodicalId":144618,"journal":{"name":"Obstetrical & Gynecological Survey","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrical & Gynecological Survey","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.ogx.0000923080.61269.5e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The use of medication abortion has increased significantly in the past several years, in part due to the increased adoption of telemedicine during the COVID-19 pandemic. Several leading organizations have established recommendations for the practice of providing a medication abortion without a prior pelvic examination or ultrasonogram (no-test medication abortion). Evidence demonstrates that gestational age can be accurately measured with patient screening questions and the risk of ectopic pregnancy among women seeking medication abortion is very low. Given this paradigm shift in abortion access, increasing numbers of health care professionals worldwide have adopted these practices and published their results. This systematic review aimed to summarize the efficacy and safety outcomes of medication abortion performed without prior pelvic examination or ultrasound. Ongoing and published clinical trials were identified, and randomized control trials and comparative cohort trials discussing the provision of no-test medication abortion were eligible. The primary study outcome was successful medication abortion, defined as complete abortion without the need for surgical management. Failure was thus defined as the need for surgical intervention to complete the abortion. Medication regimens, efficacy rates, complication rates, and adverse events were ed from eligible studies. A total of 21 studies were included in this review, including cases performed in over 24 countries. Ultimately, 15 studies were sufficiently homogenous in terms of design and comparator to create aggregate data with summary statistics for the primary outcome. The overall efficacy rate of no-test medication abortion was found to be 96.4% (95% confidence interval [CI], 96.096.7) in the 10,693 patients included in this review. Among pregnancies at less than 70 days' gestation (n = 8166), the efficacy rate was 95.2% (95% CI, 94.795.7). The rate of surgical intervention was 4.4% (95% CI, 4.04.9), and at less than 70 days' gestation was 3.8% (95% CI, 3.34.3). The ectopic pregnancy rate was 0.06% (95% CI, 0.020.15), blood transfusion rate ranged from 0% to 0.7%, and there were no deaths reported. The results of this systematic review encompassing data on 10,693 patients showed demonstrate that no-test medication abortion is likely effective and safe. The rates of surgical evacuation and complication were comparable with the rate among those undergoing medication abortion with pretreatment ultrasound, and significantly lower than the rates seen with unsafe methods of abortion.
无检测药物流产:一项系统综述
药物流产的使用在过去几年中显著增加,部分原因是在COVID-19大流行期间更多地采用了远程医疗。一些领先的组织已经建立了在没有盆腔检查或超声检查的情况下提供药物流产(无测试药物流产)的建议。有证据表明,胎龄可以通过患者筛查问题准确测量,寻求药物流产的妇女发生异位妊娠的风险非常低。鉴于堕胎机会的这种范式转变,世界各地越来越多的保健专业人员采用了这些做法并公布了其结果。本系统综述旨在总结在没有盆腔检查或超声的情况下进行药物流产的疗效和安全性。正在进行和已发表的临床试验被确定,讨论提供无检测药物流产的随机对照试验和比较队列试验符合条件。主要研究结果是成功的药物流产,定义为不需要手术治疗的完全流产。因此,流产失败被定义为需要手术干预来完成流产。用药方案、有效率、并发症发生率和不良事件均来自符合条件的研究。本综述共纳入了21项研究,包括在超过24个国家进行的病例。最终,15项研究在设计和比较器方面具有足够的同质性,可以为主要结果创建汇总数据和汇总统计数据。在本综述纳入的10693例患者中,无试验药物流产的总有效率为96.4%(95%可信区间[CI], 96.096.7)。在妊娠少于70天的孕妇中(n = 8166),有效率为95.2% (95% CI, 94.795.7)。手术干预率为4.4% (95% CI, 4.04.9),妊娠少于70天的手术干预率为3.8% (95% CI, 3.34.3)。异位妊娠率为0.06% (95% CI, 0.020.15),输血率为0% ~ 0.7%,无死亡报告。这一系统综述的结果包括10693例患者的数据表明,无测试药物流产可能是有效和安全的。手术撤离率和并发症发生率与超声预处理药物流产的发生率相当,明显低于不安全流产方法的发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信